Cargando…

Outcomes of Patients With Active Cancer and COVID-19 in the Intensive-Care Unit: A Multicenter Ambispective Study

BACKGROUND: Several studies report an increased susceptibility to SARS-CoV-2 infection in cancer patients. However, data in the intensive care unit (ICU) are scarce. RESEARCH QUESTION: We aimed to investigate the association between active cancer and mortality among patients requiring organ support...

Descripción completa

Detalles Bibliográficos
Autores principales: Plais, Henri, Labruyère, Marie, Creutin, Thibault, Nay, Paula, Plantefeve, Gaëtan, Tapponnier, Romain, Jonas, Maud, Ngapmen, Nadege Tchikangoua, Le Guennec, Loïc, De Roquetaillade, Charles, Argaud, Laurent, Jamme, Matthieu, Goulenok, Cyril, Merouani, Karim, Leclerc, Maxime, Sauneuf, Bertrand, Shidasp, Sami, Stoclin, Annabelle, Bardet, Aurélie, Mir, Olivier, Ibrahimi, Nusaibah, Llitjos, Jean-François
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8960921/
https://www.ncbi.nlm.nih.gov/pubmed/35359407
http://dx.doi.org/10.3389/fonc.2022.858276
_version_ 1784677485522190336
author Plais, Henri
Labruyère, Marie
Creutin, Thibault
Nay, Paula
Plantefeve, Gaëtan
Tapponnier, Romain
Jonas, Maud
Ngapmen, Nadege Tchikangoua
Le Guennec, Loïc
De Roquetaillade, Charles
Argaud, Laurent
Jamme, Matthieu
Goulenok, Cyril
Merouani, Karim
Leclerc, Maxime
Sauneuf, Bertrand
Shidasp, Sami
Stoclin, Annabelle
Bardet, Aurélie
Mir, Olivier
Ibrahimi, Nusaibah
Llitjos, Jean-François
author_facet Plais, Henri
Labruyère, Marie
Creutin, Thibault
Nay, Paula
Plantefeve, Gaëtan
Tapponnier, Romain
Jonas, Maud
Ngapmen, Nadege Tchikangoua
Le Guennec, Loïc
De Roquetaillade, Charles
Argaud, Laurent
Jamme, Matthieu
Goulenok, Cyril
Merouani, Karim
Leclerc, Maxime
Sauneuf, Bertrand
Shidasp, Sami
Stoclin, Annabelle
Bardet, Aurélie
Mir, Olivier
Ibrahimi, Nusaibah
Llitjos, Jean-François
author_sort Plais, Henri
collection PubMed
description BACKGROUND: Several studies report an increased susceptibility to SARS-CoV-2 infection in cancer patients. However, data in the intensive care unit (ICU) are scarce. RESEARCH QUESTION: We aimed to investigate the association between active cancer and mortality among patients requiring organ support in the ICU. STUDY DESIGN AND METHODS: In this ambispective study encompassing 17 hospitals in France, we included all adult active cancer patients with SARS-CoV-2 infection requiring organ support and admitted in ICU. For each cancer patient, we included 3 non cancer patients as controls. Patients were matched at the same ratio using the inverse probability weighting approach based on a propensity score assessing the probability of cancer at admission. Mortality at day 60 after ICU admission was compared between cancer patients and non-cancer patients using primary logistic regression analysis and secondary multivariable analyses. RESULTS: Between March 12, 2020 and March 8, 2021, 2608 patients were admitted with SARS-CoV-2 infection in our study, accounting for 2.8% of the total population of patients with SARS-CoV-2 admitted in all French ICUs within the same period. Among them, 105 (n=4%) presented with cancer (51 patients had hematological malignancy and 54 patients had solid tumors). 409 of 420 patients were included in the propensity score matching process, of whom 307 patients in the non-cancer group and 102 patients in the cancer group. 145 patients (35%) died in the ICU at day 60, 59 (56%) with cancer and 86 (27%) without cancer. In the primary logistic regression analysis, the odds ratio for death associated to cancer was 2.3 (95%CI 1.24 – 4.28, p=0.0082) higher for cancer patients than for a non-cancer patient at ICU admission. Exploratory multivariable analyses showed that solid tumor (OR: 2.344 (0.87-6.31), p=0.062) and hematological malignancies (OR: 4.144 (1.24-13.83), p=0.062) were independently associated with mortality. INTERPRETATION: Patients with cancer and requiring ICU admission for SARS-CoV-2 infection had an increased mortality, hematological malignancy harboring the higher risk in comparison to solid tumors.
format Online
Article
Text
id pubmed-8960921
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89609212022-03-30 Outcomes of Patients With Active Cancer and COVID-19 in the Intensive-Care Unit: A Multicenter Ambispective Study Plais, Henri Labruyère, Marie Creutin, Thibault Nay, Paula Plantefeve, Gaëtan Tapponnier, Romain Jonas, Maud Ngapmen, Nadege Tchikangoua Le Guennec, Loïc De Roquetaillade, Charles Argaud, Laurent Jamme, Matthieu Goulenok, Cyril Merouani, Karim Leclerc, Maxime Sauneuf, Bertrand Shidasp, Sami Stoclin, Annabelle Bardet, Aurélie Mir, Olivier Ibrahimi, Nusaibah Llitjos, Jean-François Front Oncol Oncology BACKGROUND: Several studies report an increased susceptibility to SARS-CoV-2 infection in cancer patients. However, data in the intensive care unit (ICU) are scarce. RESEARCH QUESTION: We aimed to investigate the association between active cancer and mortality among patients requiring organ support in the ICU. STUDY DESIGN AND METHODS: In this ambispective study encompassing 17 hospitals in France, we included all adult active cancer patients with SARS-CoV-2 infection requiring organ support and admitted in ICU. For each cancer patient, we included 3 non cancer patients as controls. Patients were matched at the same ratio using the inverse probability weighting approach based on a propensity score assessing the probability of cancer at admission. Mortality at day 60 after ICU admission was compared between cancer patients and non-cancer patients using primary logistic regression analysis and secondary multivariable analyses. RESULTS: Between March 12, 2020 and March 8, 2021, 2608 patients were admitted with SARS-CoV-2 infection in our study, accounting for 2.8% of the total population of patients with SARS-CoV-2 admitted in all French ICUs within the same period. Among them, 105 (n=4%) presented with cancer (51 patients had hematological malignancy and 54 patients had solid tumors). 409 of 420 patients were included in the propensity score matching process, of whom 307 patients in the non-cancer group and 102 patients in the cancer group. 145 patients (35%) died in the ICU at day 60, 59 (56%) with cancer and 86 (27%) without cancer. In the primary logistic regression analysis, the odds ratio for death associated to cancer was 2.3 (95%CI 1.24 – 4.28, p=0.0082) higher for cancer patients than for a non-cancer patient at ICU admission. Exploratory multivariable analyses showed that solid tumor (OR: 2.344 (0.87-6.31), p=0.062) and hematological malignancies (OR: 4.144 (1.24-13.83), p=0.062) were independently associated with mortality. INTERPRETATION: Patients with cancer and requiring ICU admission for SARS-CoV-2 infection had an increased mortality, hematological malignancy harboring the higher risk in comparison to solid tumors. Frontiers Media S.A. 2022-03-10 /pmc/articles/PMC8960921/ /pubmed/35359407 http://dx.doi.org/10.3389/fonc.2022.858276 Text en Copyright © 2022 Plais, Labruyère, Creutin, Nay, Plantefeve, Tapponnier, Jonas, Ngapmen, Le Guennec, De Roquetaillade, Argaud, Jamme, Goulenok, Merouani, Leclerc, Sauneuf, Shidasp, Stoclin, Bardet, Mir, Ibrahimi and Llitjos https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Plais, Henri
Labruyère, Marie
Creutin, Thibault
Nay, Paula
Plantefeve, Gaëtan
Tapponnier, Romain
Jonas, Maud
Ngapmen, Nadege Tchikangoua
Le Guennec, Loïc
De Roquetaillade, Charles
Argaud, Laurent
Jamme, Matthieu
Goulenok, Cyril
Merouani, Karim
Leclerc, Maxime
Sauneuf, Bertrand
Shidasp, Sami
Stoclin, Annabelle
Bardet, Aurélie
Mir, Olivier
Ibrahimi, Nusaibah
Llitjos, Jean-François
Outcomes of Patients With Active Cancer and COVID-19 in the Intensive-Care Unit: A Multicenter Ambispective Study
title Outcomes of Patients With Active Cancer and COVID-19 in the Intensive-Care Unit: A Multicenter Ambispective Study
title_full Outcomes of Patients With Active Cancer and COVID-19 in the Intensive-Care Unit: A Multicenter Ambispective Study
title_fullStr Outcomes of Patients With Active Cancer and COVID-19 in the Intensive-Care Unit: A Multicenter Ambispective Study
title_full_unstemmed Outcomes of Patients With Active Cancer and COVID-19 in the Intensive-Care Unit: A Multicenter Ambispective Study
title_short Outcomes of Patients With Active Cancer and COVID-19 in the Intensive-Care Unit: A Multicenter Ambispective Study
title_sort outcomes of patients with active cancer and covid-19 in the intensive-care unit: a multicenter ambispective study
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8960921/
https://www.ncbi.nlm.nih.gov/pubmed/35359407
http://dx.doi.org/10.3389/fonc.2022.858276
work_keys_str_mv AT plaishenri outcomesofpatientswithactivecancerandcovid19intheintensivecareunitamulticenterambispectivestudy
AT labruyeremarie outcomesofpatientswithactivecancerandcovid19intheintensivecareunitamulticenterambispectivestudy
AT creutinthibault outcomesofpatientswithactivecancerandcovid19intheintensivecareunitamulticenterambispectivestudy
AT naypaula outcomesofpatientswithactivecancerandcovid19intheintensivecareunitamulticenterambispectivestudy
AT plantefevegaetan outcomesofpatientswithactivecancerandcovid19intheintensivecareunitamulticenterambispectivestudy
AT tapponnierromain outcomesofpatientswithactivecancerandcovid19intheintensivecareunitamulticenterambispectivestudy
AT jonasmaud outcomesofpatientswithactivecancerandcovid19intheintensivecareunitamulticenterambispectivestudy
AT ngapmennadegetchikangoua outcomesofpatientswithactivecancerandcovid19intheintensivecareunitamulticenterambispectivestudy
AT leguennecloic outcomesofpatientswithactivecancerandcovid19intheintensivecareunitamulticenterambispectivestudy
AT deroquetailladecharles outcomesofpatientswithactivecancerandcovid19intheintensivecareunitamulticenterambispectivestudy
AT argaudlaurent outcomesofpatientswithactivecancerandcovid19intheintensivecareunitamulticenterambispectivestudy
AT jammematthieu outcomesofpatientswithactivecancerandcovid19intheintensivecareunitamulticenterambispectivestudy
AT goulenokcyril outcomesofpatientswithactivecancerandcovid19intheintensivecareunitamulticenterambispectivestudy
AT merouanikarim outcomesofpatientswithactivecancerandcovid19intheintensivecareunitamulticenterambispectivestudy
AT leclercmaxime outcomesofpatientswithactivecancerandcovid19intheintensivecareunitamulticenterambispectivestudy
AT sauneufbertrand outcomesofpatientswithactivecancerandcovid19intheintensivecareunitamulticenterambispectivestudy
AT shidaspsami outcomesofpatientswithactivecancerandcovid19intheintensivecareunitamulticenterambispectivestudy
AT stoclinannabelle outcomesofpatientswithactivecancerandcovid19intheintensivecareunitamulticenterambispectivestudy
AT bardetaurelie outcomesofpatientswithactivecancerandcovid19intheintensivecareunitamulticenterambispectivestudy
AT mirolivier outcomesofpatientswithactivecancerandcovid19intheintensivecareunitamulticenterambispectivestudy
AT ibrahiminusaibah outcomesofpatientswithactivecancerandcovid19intheintensivecareunitamulticenterambispectivestudy
AT llitjosjeanfrancois outcomesofpatientswithactivecancerandcovid19intheintensivecareunitamulticenterambispectivestudy